Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

ClinicalTrials.gov ID: NCT02341417

Public ClinicalTrials.gov record NCT02341417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease on Dialysis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study was to characterize the long-term safety and tolerability of cinacalcet in pediatric patients with chronic kidney disease (CKD) receiving dialysis.

Study identification

NCT ID
NCT02341417
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
28 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Up to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 10, 2015 (Actual)
Primary completion
Mar 15, 2017 (Actual)
Completion
Mar 15, 2017 (Actual)
Last update posted
Jun 29, 2020

2015 – 2017

United States locations

U.S. sites
18
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
Research Site Los Angeles California 90027 —
Research Site Tucker Georgia 30084 —
Research Site Baltimore Maryland 21287 —
Research Site Boston Massachusetts 02115 —
Research Site Minneapolis Minnesota 55454 —
Research Site Jackson Mississippi 39216 —
Research Site Kansas City Missouri 64108 —
Research Site St Louis Missouri 63110 —
Research Site West Orange New Jersey 07052 —
Research Site New York New York 10029 —
Research Site Greenville North Carolina 27834 —
Research Site Cincinnati Ohio 45229 —
Research Site Cleveland Ohio 44195 —
Research Site Columbus Ohio 43205 —
Research Site Oklahoma City Oklahoma 73104 —
Research Site Dallas Texas 75235 —
Research Site Houston Texas 77030 —
Research Site Salt Lake City Utah 84113 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02341417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 29, 2020 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02341417 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →